

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appln. No: 10/751,611  
Applicants: Derek Wyndham Clissold et al.  
Filed: January 5, 2004  
Title: PROSTAGLANDIN SYNTHESIS  
TC/A.U.: 1621  
Examiner:

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO 1449 (RP) submitted herewith. A copy of each of the listed references, except for the listed U.S. patent, is also enclosed.

Although the information submitted herewith may be "material" to the Examiner's consideration of the subject application, this submission is not intended to constitute an admission that such information is "prior art" as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

The Japanese references, Nos. 1-228933, 60-166639, 59-44336 and 57-171965, are not in the English language, but English abstracts thereof are attached to each copy of the references submitted herewith. Also, these references were cited by a foreign patent office in a counterpart foreign application. A copy of this English language search report, indicating the degree of relevance determined by the foreign patent office is submitted herewith. MPEP Section 609A(3), second paragraph.

The Chinese reference entitled "Synthesis of the Antiglaucoma Drug Latanoprost and its Effect on Reduction of Intraocular Pressure (IOP)" is not in the English language, but an English abstract thereof is attached to the copy of the reference submitted herewith. Also, the

applicants refer the Examiner to the synthetic scheme on pages 213 and 214, which does not require translation.

This Information Disclosure Statement is being filed before mailing of the first Official Action. No first Official Action has yet been received and it is presumed that none has yet been mailed. No fee or statement is required. 37 C.F.R. § 1.97(b).

Respectfully submitted,



Christopher R. Lewis, Reg. No. 36,201  
Attorney for Applicants

CRL/lrb

Enclosures: Forms PTO/SB/08A (1 pg.) and  
PTO/SB/08B (1 pg.)  
Copy of ten (10) references  
Copy of British Search Report

Dated: July 9, 2004


P.O. Box 980  
Valley Forge, PA 19482-0980  
(610) 407-0700

The Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. 18-0350 of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

July 9, 2004

Date



Christopher R. Lewis

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/751,611
Filing Date	January 5, 2004
First Named Inventor	Derek Wyndham Clissold
Art Unit	1621
Examiner Name	
Attorney Docket No.	JMYT-314US

SHEET 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US-3,920,723	11-18-1975	Nelson	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	2	EP-0 178 139-A3	04-16-1986	Teijin Limited		<input type="checkbox"/>
	3	GB-1 582 853	01-14-1981	Imperial Chemical Industries Limited		<input type="checkbox"/>
	4	JP-1-228933	09-12-1989	Fumie Satao		<input type="checkbox"/>
	5	JP-60-166639	08-29-1985	Sagami Chuo Kagaku Kenkyusho		<input type="checkbox"/>
	6	JP-59-44336	03-12-1984	Teijin Limited		<input type="checkbox"/>
	7	JP-57-171965	10-22-1982	Teijin Limited		<input type="checkbox"/>
	8	WO-02/096868	12-05-2002	Finetech Laboratories Ltd.		<input type="checkbox"/>
	9	WO-02/090324	11-14-2002	Yonsung Fine Chemical Co.		<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard St.3).

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449B/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/751,611
Filing Date	January 5, 2004
First Named Inventor	Derek Wyndham Clissold
Art Unit	1621
Examiner Name	
Attorney Docket No.	JMYT-314US

SHEET 2 of 2

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	10	Paul W. Collins and Stevan W. Djuric, "Synthesis of Therapeutically Useful Prostaglandin and Prostacyclin Analogs," <i>Chem. Rev.</i> , 1993, Vol. 4, pp. 1533-1564.	<input type="checkbox"/>
	11	Chen Jianxing, Chen Hailin, and Chen Liangkang, "Synthesis of the Antiglaucoma Drug Latanoprost and its Effect on Reduction of Intraocular Pressure (IOP)," <i>Chinese Journal of Medicinal Chemistry</i> , September 1988, Vol. 8, No. 3, pp. 213-217.	<input type="checkbox"/>
	12	British Search Report dated May 4, 2004, from British Application No. 0329379.2.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>1</sup>Applicant's unique citation designation number (optional).

<sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.